Antivirals, Vaccines and Molecular Tools for Viral Pathogens
Maurice Wilkins Centre investigators are collaborating on research that aims to tackle a variety of viral infectious diseases.
This flagship is a broad team-based collaboration bringing together world-class scientists from a range of disciplines - biology, chemistry, structure-based design, manufacture and translation. It also has the benefit of being able to leverage existing funding, as well as national and international collaborations that span the antiviral development sphere.
A feature of this flagship is that it comprises of four main research themes focused on different types of virus – influenza, arbovirus, norovirus and hepatitis B.
Within the influenza theme, we are utilising structure based methods to identify new candidate antivirals that interfere with viral replication. In addition we are using new technologies to design broader, more effective anti-influenza vaccines.
Our researchers are also working to develop novel direct acting antivirals that target a range of arboviruses such as the dengue virus, which are prevalent in the Asia Pacific region.
In addition, we are seeking to develop new treatments for norovirus (a bug that causes diarrhoea and vomiting) using a novel assay that targets key functional domains in viral proteins.
The fourth theme within this flagship is devoted to the hepatitis B virus and has two primary objectives: (1) to develop an effective antiviral agent and (2) to develop a vaccine that is effective in cases of chronic active hepatitis.